As of November 6, 2026, uniQure N.V. is a publicly traded company (Nasdaq: QURE); its largest reported holder is Avoro Capital Advisors LLC, with 9.87% on Schedule 13G/A of February 17, 2026, then JPMorgan Chase (8.5%). The largest insider holding is Matthew C. Kapusta, the chief executive and a director, with 519,227 shares (0.74% of shares outstanding), per Form 4 of July 7, 2026 (Schedule 13G/A, February 17, 2026).
Is this your company?
About to sign with, pay or invest in uniQure N.V.? See the free Snapshot first.
Free to see. No signup.
Is uniQure N.V. a real, registered company?
- uniQure N.V. files with the SEC under CIK 1590560 (its SEC filings).
- Its shares are listed under the ticker QURE on Nasdaq (SEC company record).
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under uniQure N.V. in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names JPMorgan Chase (filed 2026-10-16).
Who are uniQure N.V.'s owners and officers?
uniQure N.V.: industry Pharmaceutical Preparations (Schedule 13G/A, 2026-10-16).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-10-16 | Jpmorgan Chase & Co. | 8.5% |
| Schedule 13G, 2026-08-14 | Rtw Investments, LP | 5.7% |
| Schedule 13G/A, 2026-08-14 | G1 Execution Services, LLC | 4.8% |
| Schedule 13G/A, 2026-07-20 | Aberdeen Group PLC | 4.52% |
| Schedule 13G, 2026-07-16 | Jpmorgan Chase & Co | 7% |
| Schedule 13G/A, 2026-05-15 | Rtw Investments, LP | 4.1% |
| Schedule 13G, 2026-05-12 | State Street Corporation | 3.6% |
| Schedule 13G/A, 2026-05-06 | Fmr LLC | 2.8% |
| Schedule 13G/A, 2026-04-30 | Aberdeen Group PLC | 8.49% |
| Schedule 13G/A, 2026-02-17 | Avoro Capital Advisors LLC | 9.87% |
| Schedule 13G/A, 2026-02-17 | Rtw Investments, LP | 6% |
| Schedule 13G/A, 2026-02-17 | Ecor1 Capital, LLC | 0% |
Questions about who owns uniQure N.V.
Who owns uniQure N.V.?
On this page, 4 holders' latest ownership filings report 5% or more of uniQure N.V.: Avoro Capital Advisors LLC (9.87%, Schedule 13G/A, filed 2026-02-17), Jpmorgan Chase & Co. (8.5%, Schedule 13G/A, filed 2026-10-16), Jpmorgan Chase & Co (7%, Schedule 13G, filed 2026-07-16) and Rtw Investments, LP (5.7%, Schedule 13G, filed 2026-08-14).
Who are the largest shareholders of uniQure N.V.?
By the share each holder's latest filing reports, the largest holders of uniQure N.V. on this page are Avoro Capital Advisors LLC (9.87%), Jpmorgan Chase & Co. (8.5%) and Jpmorgan Chase & Co (7%).
When did Avoro Capital Advisors LLC buy into uniQure N.V.?
The filings give report dates, not purchase dates. The earliest filing from Avoro Capital Advisors LLC on this page is the Schedule 13G/A, filed 2026-02-17, reporting 9.87%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on uniQure N.V.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on uniQure N.V.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on uniQure N.V. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
18 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own uniQure N.V. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , the chief executive and a director: 519,227 shares (0.74% of shares outstanding) (Form 4, 2026-07-07).
- , the chief financial officer: 226,581 shares (0.32% of shares outstanding) (Form 4, 2026-03-06).
- , the chief medical officer: 166,985 shares (0.24% of shares outstanding) (Form 4, 2026-11-03).
- , the chief legal officer: 133,246 shares (0.19% of shares outstanding) (Form 4, 2026-06-17).
- , the chief customer and strat officer: 108,864 shares (0.16% of shares outstanding) (Form 4, 2026-06-12).
Shares outstanding: 70,138,860 as of 2026-11-02, from the company's latest SEC cover page.
How much has uniQure N.V. raised?
No fundraising or offering filing from uniQure N.V. is on file with us.
Keep reading
More on uniQure N.V. and the records around it.
uniQure N.V. elsewhere on the record
- 5%+ stake filings Oct 2026
Companies that share a holder
- Aberdeen Group plc also filed stake reports on 12 other companies: Equillium, Inc. (Nov 2026), IMMUNIC, INC (Nov 2026), CODEXIS, INC. (Oct 2026)
- Avoro Capital Advisors LLC also filed stake reports on 18 other companies: Arrowhead Pharmaceuticals, Inc. (Aug 2026), Avalo Therapeutics, Inc. (Aug 2026), Hemab Therapeutics Holdings, Inc. (Aug 2026)
- EcoR1 Capital, LLC also filed stake reports on 20 other companies: Mereo BioPharma Group plc (Aug 2026), Alto Neuroscience, Inc. (Jul 2026), Fulcrum Therapeutics, Inc. (Jun 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/uniqure-nv